Farmagora SA
3.1 FTEFarmagora reported total assets of €1.78m at the end of the 2025 financial year (annual accounts filed with the NBB on 31 Jul 2026), with 3.1 full-time equivalents.
The score of Farmagora shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity 0 % Total assets -9 % Headcount (avg FTE) 0 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Farmagora's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 31 Jul 2026
- Year ended 31 Dec 2024filed on 30 Jul 2025
- Year ended 31 Dec 2023filed on 25 Jul 2024
- Year ended 31 Dec 2022filed on 27 Jul 2023
- Year ended 31 Dec 2021filed on 27 Jul 2022
Farmagora's financial analysis
- Solvency89.3%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Farmagora
Farmagora's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0436.025.193
- VAT number
- BE0436025193
- Peppol
- Registered · 0208:0436025193 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 07 Dec 1988
- Registered office
- 1740 Ternat
- Size
- Micro · 3.1 FTE
- Latest accounts
- 2025 · filed on 31 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Farmagora (SA) has been based in Ternat since 1988, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 3,424 € and equity of €1.59m; its revenue is not published. With 3.1 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 89.3%, above the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Farmagora
Companies in the same business, of comparable size and area, outside its group.
- Inge Thoelen Retail sale of pharmaceutical products Landen · balance sheet €1.74m
- Phargest Retail sale of pharmaceutical products Profondeville · balance sheet €1.78m
- Pharmacie du Laveu Retail sale of pharmaceutical products Liège · balance sheet €1.78m
- Apotheek Dirk van Herck Retail sale of pharmaceutical products Nijlen · balance sheet €1.77m
- D4-Pharma Retail sale of pharmaceutical products Etterbeek · balance sheet €1.77m
- Bytebier Kaatje Retail sale of pharmaceutical products Boechout · balance sheet €1.80m
- Selvais Retail sale of pharmaceutical products Bastogne · balance sheet €1.75m
- Hampharma Retail sale of pharmaceutical products Tessenderlo-Ham · balance sheet €1.75m
Frequently asked questions about Farmagora
What is the revenue of Farmagora?
Farmagora files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Farmagora?
In Belgium, the VAT number is the company number prefixed with BE: BE0436025193 for Farmagora, if the company is VAT-registered. Its company number (CBE) is 0436.025.193.
Where is the registered office of Farmagora?
According to the CBE register, the registered office of Farmagora is in 1740 Ternat.
What is the equity of Farmagora?
At the close of the 2025 financial year, the equity of Farmagora amounts to 1,590,526 €, a solvency of 89.3% of total assets.
How many people work at Farmagora?
3.1 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Farmagora?
The register lists 4 active mandates at Farmagora. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Farmagora
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →